GS Healthcare NYC
Anyone has updated thoughts/opinions on GS Healthcare and how it compares to other groups at GS and top groups at other BBs in terms of placement and culture? Are exit opps limited to the healthcare group at PE firms? Thanks
Trending Content
| +173 | The "Not So Obvious" things that get you a return offer? | 20 | 11h | |
| +110 | Is my life over after not getting GS? | 27 | 2h | |
| +70 | Best IB group on the Street | 31 | 1h | |
| +58 | BIG FOUR ARE PARADISE | 15 | 13h | |
| +50 | Thoughts and tips on how to speak like an investment banker. | 25 | 13h | |
| +48 | Tell me one good reason why Jefferies isn’t going to be a top bank in the next 5 years | 23 | 5h | |
| +36 | UBS Outlook | 28 | 1d | |
| +35 | How to deal with egotistical team? | 6 | 3d | |
| +33 | Highest Paid Bankers in Toronto? | 51 | 11h | |
| +25 | Got RBC offer but I have cold feet accepting. | 34 | 12m |
Career Resources
bump
In the Life Sciences spaces (Pharma, Biotech, Devices), they have not really been competitive with other BB's in terms of M&A (only mega deal they've been on from Q1 2017 - Q1 2018 was Becton Dickson/Bard). They have gotten lead roles on some of the larger equity offerings (Alnylam, bluebird, Sage, Agios) over that same time period, but this has been a relatively recent phenomenon. It will be interesting to see if they are able to convert these to M&A assignments.
I can't speak to their strengths on the healthcare services side.
As far as exits go, the one person I knew in that group went on to do Healthcare PE at Apax Partners before leaving for CorpDev.
So in terms of competitive position in Healthcare, its probably not the best group. However, the Goldman name alone is probably strong enough to yield good exits.,..
Ok... was the person you know a top performer in the group? If so, it seems that the exit opps are not great compared to the top groups at GS/MS/JPM? It's interesting that some older posts suggest that GS HC is one of the top HC groups on the street, why has this changed over the past few years? Also, do you have any information on how hard it is to transition into another group (e.g. Tech) at a PE firm after the two-year program? Thank you!
Sorry only just saw this.....I don't know if the person was a top performer in the group or not. I do know the person was pretty dissatisfied with the mundane nature of the work they were regularly asked to do (pretty common complaint in banking). So, the person by no means "drank the Goldman kool-aid". It probably doesn't yield exits as good as those in the top groups at GS/MS/JPM but the exits it does yield are certainly nothing to shrug at.
As to why Goldman's position may have changed over the past few years, maybe it has something to do with Jack Levy and Andrew Rymer joining Centerview. Centerview has been absolutely crushing it in Life Sciences M&A recently. I've heard Jack Levy spoken of as some sort of Healthcare banking savant. Maybe those M&A deals that Goldman would have been on in the past are now going to Centerview?
I imagine its not difficult to transition into Tech post-MBA, which is the route most PE Associates go. If you are going to get promoted at the PE shop however, I don't think you'll be able to transition given that the people promoting you are the ones whom you're working with (i.e. the Healthcare investment professionals).
Spot on. It absolutely has to do with Jack Levy and Andrew Rymer. On any given large healthcare M&A deal there is a very good chance CVP will be on it.
Just discovered that CapIQ sporadically names the bankers that worked on the transactions. It doesn't do it for every deal but for all the deals which it does, Alan Hartman and Mark Robinson are named. So, it doesn't seem like CVP's success in the space is because of Levy and Rymer after all.
I think Levy and Rymer are still great, but from speaking to people at CVP. Mark Robinson in particular has done a stellar job of transforming CVP into the top sell-side healthcare bank. Examples: AveXis to Novartis, Kite Pharma to Gilead The CVP team is doing significantly more sell-sides than buy-sides (Mark Robinsons' area of expertise) hence you see him on a lot of deals.
This is pretty interesting as in Life Sciences, these sell-side mandates are usually awarded to the firms that underwrote the company's equity offerings (makes sense as the M&A assignment is the reward for long periods of consistent coverage). You'll still see a balance sheet bank on these assignments along with CVP (i.e. AveXis also used GS and Kite used Cowen and Jefferies), but CVP is displacing someone by convincing these companies to forsake a long-term relationship in favor of their M&A "expertise".
Then again, maybe they aren't displacing anyone and are just convincing companies to split the fee that would otherwise all go to the balance sheet bank in which case, I'd love to know how these guys are combating that.
It's honestly pretty incredible. CVP has really established itself as an incredible trusted advisor for biotech companies. Speaking with an MD there, I learned that CVP is by far the leader in sell-side healthcare deals. Some of the relationships are being newly built off their past track record, and some based on legacy connections. Take for example, AveXis. The CEO at AveXis, Sean Nolan, was also the CBO at InterMune which was sold in 2014 to Roche for $8.3 billion (InterMune was also advised by Centerview).
I'd say CVP is really displacing other companies because of their "expertise". They only get paid based on M&A transactions. In the case of AveXis, the MD with the relationship shared that Nolan was interested in selling 2 years ago, but was advised not to after seeing what bids came in. CVP really tries to pitch their value aka the fact that aren't incentivized to push M&A and get financing (where big banks are really making their moolah). They are okay with long-term relationships (which are getting built with these biotech companies at practically the start-up stage). Is CVP truly so much better? No clue, but they are winning.
This is pretty incredible insight. However, over the LTM CVP has been on the sell-side for 9 HC M&A transactions whereas JPM has been on 19 (did a quick CapIQ search). Maybe if you look at fees or among boutiques only, they are the "leader" but I still think they're well behind the JPM HC franchise.
Your point about them being LESS motivated to push M&A than the BB's because of financing fees is definitely valid but, at the end of the day, they are definitely still bankers trying to push M&A. If you get a chance, give this read....
http://fortune.com/go/finance/carl-icahn-blocked-xerox-merger-fujifilm/
The CVP banker, David Hess, undoubtedly knew that the deal the Xerox CEO was pushing was bad for shareholders yet CVP proposed and were executing on the structure anyway. So CVP's schtick that they're not pushing M&A is not as universal as they're marketing would suggest.
Ultimately, I don't believe M&A is rocket science and there is little discernible difference between the value that one (industry focused) M&A advisor provides over another. What differentiates bankers is their efforts to build long-term relationships with clients which is facilitated by offering underwriting, research coverage, etc. That Mark Robinson displaced the Jefferies or BAML HC team (both of whom worked on multiple equity offerings for AveXis) because he is supposedly so much better at sell-side M&A is frustrating and bad for banking because it results in a consolidation of "attractive" advisory assignments (and all the benefits that come with it) among older, entrenched bankers whom almost certainly did not work as hard for the company as the younger bankers at Jefferies or BAML on multiple offerings over long periods of time.
Can't do public company sell side and finance the transaction too. So mute point that people are trying to push financing to get sell side. Works for staples in private company sell sides but those PE guys know when to sell their portfolio company anyway. Don't need a banker to advise on timing
Actually these guys are doing quite a bit https://www.prnewswire.com/news-releases/stuart-smith-and-michael-muntn…
Anyone else has insights to share on GS Healthcare?
Also was wondering. And is healthcare now completely combined with the Consumer & Retail group?
I think they are completely separate now...
Aut quia laudantium quasi quam. Nobis omnis qui quis natus et laborum.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...